05th week of 2009 patent applcation highlights part 49 |
Patent application number | Title | Published |
20090029918 | Method for producing mature VWF from VWF Pro-Peptide - The present invention relates to a method for producing a mature von Willebrand Factor (VWF) from von Willebrand Factor pro-peptide comprising the steps:
| 2009-01-29 |
20090029919 | Leptin peptide antagonists - Disclosed herein are peptides comprising a leptin sequence and methods for their use in preventing ObR signaling in a leptin-responsive cell. A leptin peptide of the present invention binds to but does not activate ObR signaling in a leptin-responsive cell, thereby inhibiting the up-regulatory effects of leptin on ObR signaling in the leptin-responsive cell. Administration of the peptide effectively prevents embryo implantation in a mammal to which the peptide has been administered. Also disclosed herein is a method for identifying a peptide antagonist of ObR, wherein the peptide comprises a leptin sequence. | 2009-01-29 |
20090029920 | Methods and Compositions for Treating Ocular Disorders - The present invention provides a method for treating and/or preventing damage to a retina or optic nerve in a subject comprising administering to the subject a therapeutically effective amount of oncomodulin. Preferably, the subject is a mammal, most preferably, a human. In preferred embodiments, the oncomodulin may be used in combination with mannose, a mannose derivative and/or inosine. | 2009-01-29 |
20090029921 | Method for Removing Endotoxin from Proteins - Disclosed is a method for removing endotoxin from proteins. Also disclosed are products made by using the method. The method may be used, for example, to produce endotoxin-free lactoferrin. Bovine milk-derived lactoferrin may be produced in commercial quantities by the method, and endotoxin-free bovine lactoferrin may be used for a variety of therapeutic uses, including improving wound healing. | 2009-01-29 |
20090029922 | Use of S1P receptor agonists in heart diseases - The invention relates to the use of a sphingosine-1-phosphate receptor agonist in the treatment of heart diseases. | 2009-01-29 |
20090029923 | Use of thrombin-derived peptides for the therapy of chronic dermal ulcers - Disclosed is a method of promoting healing of a chronic dermal skin ulcer, such as a diabetic ulcer, on a subject. The method comprises the step of contacting the chronic dermal skin ulcer with an effective amount of an agonist of the non-proteolytically activated thrombin receptor. | 2009-01-29 |
20090029924 | Targeting Host Proteinases as a Therapeutic Strategy Against Viral and Bacterial Pathogens - Disclosed are compositions and methods for preventing or reducing harm resulting from pathogen infection. For example, disclosed are peptides that inhibit the processing of toxins normally cleaved by proprotein convertase enzymes. | 2009-01-29 |
20090029925 | INTERACTION OF BIM WITH TRIM2, AN E3 UBIQUITIN LIGASE - Methods, compositions, and cells for drug screening based on interaction between (1) a Bim polypeptide and/or an E2 polypeptide and (2) a TRIM2 polypeptide, which is identical to or corresponds to a Bim-selective E3 ubiquitin ligase. Methods and compositions for treating cancer based on levels of Bim protein, TRIM2 protein, and active MAPK protein are also provided. | 2009-01-29 |
20090029926 | Lys-thr dipeptides and their use - Dipeptides and derivatives and analogs, such as Pal-KT have been developed. These dipeptides, derivatives and analogs may be used alone or in an additive, to produce cosmetics, topical pharmaceuticals and personal care products, particularly for skin care. Methods of making the dipeptides, derivatives, analogs and additives containing same are also described. | 2009-01-29 |
20090029927 | COMPOUNDS HAVING INHIBITORY ACTIVITY AGAINST SODIUM-DEPENDENT GLUCOSE TRANSPORTER - The invention is directed to compounds of the formula (I) described herein, a pharmaceutically acceptable salt thereof, or a prodrug thereof, and pharmaceutical compositions and methods of treatment. | 2009-01-29 |
20090029928 | PEELING PROCESS AND COMPOSITION - Process for the treatment of visible and/or tactile irregularities of human skin, by applying topically, to the skin, a composition containing at least one hydroxy acid chosen from α-hydroxy acids, β-hydroxy acids, α-keto acids, β-keto acids, and mixtures thereof, and at least one cationic polymer, leaving the composition in contact with the skin for a period of time sufficient for the composition to act, and optionally, removing the composition by rinsing. Associated compositions. | 2009-01-29 |
20090029929 | Decoy Nucleic Acid to Synoviolin Gene Promoter - The present invention provides a decoy nucleic acid for the Synoviolin gene promoter. Also provided is the decoy nucleic acid can inhibit the promoter activity by binding to the transcription factor of the Synoviolin gene promoter. It also provides a decoy nucleic acid as expressed in (a) a decoy nucleic acid consisting of a nucleotide sequence as shown in SEQ ID NO: 11 or 12; and it also provides (b) a decoy nucleic acid consisting of a nucleotide sequence as shown in SEQ ID NO: 11 or 12 having deletion, substitution or addition of one or several nucleotides and has the function of inhibiting Synoviolin gene promoter activity. | 2009-01-29 |
20090029930 | Methods of gene therapy using nucleic acid sequences for ATP-binding cassette transporter - The present invention provides nucleic acid and amino acid sequences of an ATP binding cassette transporter and mutated sequences thereof associated with macular degeneration. Methods of detecting agents that modify ATP-binding cassette transporter comprising combining purified ATP binding cassette transporter and at least one agent suspected of modifying the ATP binding cassette transporter an observing a change in at least one characteristic associated with ATP binding cassette transporter. Methods of detecting macular degeneration is also embodied by the present invention. | 2009-01-29 |
20090029931 | Topical administrations of antisense compounds to vla-4 for the treatment of respiratory conditions - A method for the treatment and/or prophylaxis of an animal having a respiratory disease or condition associated with airway hyperresponsiveness, eosinophilia, neutrophilia, leukocytes or overproduction of mucus and/or with the expression of integrin α4 comprising administering to the animal a composition comprising from. 0.001 to 1000 μg per kg body weight of the animal of an antisense compound targeted to a nucleic acid molecule encoding integrin α4. | 2009-01-29 |
20090029932 | Identification and use of miRNAs for differentiating myeloid leukemia cells - The invention relates to the use of nucleic acid miRNA derived molecules for producing a drug for treating a myelogenous leukemia and to a method for identifying therapeutic agents or the efficient combination thereof for inducing the differentiation of myelogenous leukemia cells. | 2009-01-29 |
20090029933 | INHIBITOR OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ALPHA COACTIVATOR 1 - The present invention refers to the use of an antisense DNA oligonucleotide for the messenger RNA of the PGC-1α protein, useful as drug for the treatment of diabetes mellitus, insulin resistance and metabolic syndrome. More specifically, the present invention deals with a compound used as drug, through enteral or parenteral route, preferably, with the property of inhibiting the protein expression peroxisome proliferator-activated receptor alpha Coactivator 1 (PGC-1α) leading to the reduction of the blood glucose levels. It deals, therefore, with a pharmacological compound that promotes, in diabetic and insulin-resistant individuals, improvement of the glucose serum levels, increase of the plasmatic insulin concentration and reduction of insulin resistance. The present invention presents a more effective control of the glucose levels and acts beneficially on other complications associated to the Diabetes and obesity conditions, according to tests performed in animal models. In this manner, the principal advantage of the present invention over others alike already existing in the market is the effectiveness that controls blood glucose levels and the fact of acting beneficially on other complications that accompany the disease. | 2009-01-29 |
20090029934 | RNA interference in respiratory epithelial cells - The present invention is directed to small interfering RNA molecules targeted against a gene of interest in respiratory epithelial cells, and methods of using these RNA molecules. | 2009-01-29 |
20090029935 | Centrosomal proteins and secretion - Described are methods for modulating cellular secretion, and methods for identifying novel modulators of cellular secretion, that target centrosomal proteins. | 2009-01-29 |
20090029936 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION BY DOUBLE-STRANDED RNA - The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery. | 2009-01-29 |
20090029937 | BIODEGRADABLE CATIONIC POLYMER GENE TRANSFER COMPOSITIONS AND METHODS OF USE - The invention provides biodegradable, cationic compositions based on cationic α-amino acid-containing PEA, PEUR and PEU polymers for use in preparation of non-viral gene transfer compositions. In the invention gene transfer compositions a poly nucleic acid is condensed with the polymer to form a soluble unit wherein the electrical charge of the poly nucleic acid is neutralized by the polymers. The invention gene transfer compositions can be used to transfect target cells by contact with the target cells. | 2009-01-29 |
20090029938 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATING DISEASE INCLUDING INFLAMMATORY CONDITIONS - The invention relates to therapeutic antisense oligonucleotides directed against genes coding for phosphodiesterase (PDEs) and the use of these in combination. These antisense oligonucleotides may be used as analytical tools and/or as therapeutic agents in the treatment of disease associated with reduced cellular cAMP in a patient, such as inflammatory diseases of the respiratory tract including, for example, asthma, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, bronchitis, chronic bronchitis, silicosis, pulmonary fibrosis, lung allograft rejection, allergic rhinitis and chronic sinusitis as well as other conditions in which an increase in cyclic AMP or a decrease in PDE levels is beneficial. | 2009-01-29 |
20090029939 | Pre-organized tricyclic integrase inhibitor compounds - Tricyclic compounds according to the structure below, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed. | 2009-01-29 |
20090029940 | Plymorphic form of inulin and uses thereof - The present invention relates to a new polymorphic form of inulin, designated delta inulin (dIN), to methods for the preparation of dIN, compositions comprising dIN and uses thereof. The present invention also relates to the use of dIN and compositions comprising dIN in the preparation of gamma inulin (gIN), compositions comprising gIN and uses thereof. | 2009-01-29 |
20090029941 | METHODS FOR CELL MOBILIZATION USING IN VIVO TREATMENT WITH HYALURONAN (HA) - The use of forms of hyaluronic acid having a molecular weight less than about 750,000 daltons selected from the group consisting of hyaluronic acid and pharmaceutically acceptable salts thereof is provided for the same purposes known for using recombinant GM-CSF or G-CSF. | 2009-01-29 |
20090029942 | ADMINISTRATION OF COPPER TO AN ANIMAL - The present invention is directed to the administration of copper to an animal using a composition containing copper dextran. A method is described for increasing the copper levels in an animal by the administration of a composition containing copper dextran. A preferred method of administration is intra muscularly. The use of this composition has been found to both address copper deficiencies in an animal, particularly deer. | 2009-01-29 |
20090029943 | Glucosamine and Derivatives Thereof Useful as TG Inhibitors - Disclosed herein is a transglutaminase inhibitor comprising glucosamine or a derivative thereof. Exhibiting potent inhibitory activity against transglutaminase, the overexpression of which is responsible for the etiology of various diseases, glucosamine or derivatives thereof can be useful in the prevention and treatment of such diseases. Also, a pharmaceutical composition comprising glucosamine or a derivative thereof as an active ingredient and a method of inhibiting transglutaminase are disclosed. Featuring the use of the pharmaceutical composition, the method can be therapeutically safely and effectively-applied to patients afflicted with such diseases. | 2009-01-29 |
20090029944 | METHODS FOR ADDING FATTY ACIDS TO AGENTS IN AQUEOUS SOLUTION TO IMPROVE BIOAVAILABILITY - Adding fatty acids to agents enhances deliverability of the antioxidant, making the agent less likely to be degraded prior to intercellular delivery. Additionally, adding fatty acids to agents provides a time lapse-type mechanism to the agents. Fatty acid modified agents are made with a novel process in aqueous solution, reducing the need to use organic solvents. Agents that can be modified as disclosed herein include nearly any biological molecule that have hydroxyl, amine, or sulphydryl sites, including antioxidants, such as glutathione and polyphenols (e.g., ECGC, curcumin, or resveratol), saccharides, such as glucosamine, and other glycans. | 2009-01-29 |
20090029945 | Non-Anilinic Derivatives of Isothiazol-3(2H)-Thione 1,1-Dioxides As Liver X Receptor Modulators -
The present invention relates to certain novel compounds of the formula (I)
| 2009-01-29 |
20090029946 | Aqueous oral solution of bisphosphonic acid - The present invention relates to stable aqueous oral formulation of bisphosphonic acid or its pharmaceutically acceptable salts. More particularly, the present invention relates to stable aqueous oral formulation of alendronate sodium. The present invention also relates to a process for the preparation of stable aqueous oral formulation of alendronate sodium. | 2009-01-29 |
20090029947 | Sphingosine-1-phosphate receptor agonist and antagonist compounds - The present invention is directed to novel, potent, and selective agents, which are agonists or antagonists of the one or more of the individual receptors of the S1P receptor family. The compounds of the invention are useful as therapeutics for treating medical conditions associated with agonism or antagonism of the individual receptors of the S1P receptor family. | 2009-01-29 |
20090029948 | Organic Derivatives, Their Salts and Use for the Control of Phytopathogens - Organic compounds are described, which are capable of forming quaternary salts, quaternary salts thereof with a structure having general formula (I) and their use for the control of phytopathogen fungi. | 2009-01-29 |
20090029949 | GPCR Ligands Identified by Computational Modeling - Disclosed are pharmacophores for developing and screening compounds having G-protein-coupled receptor antagonist activity, including LPA | 2009-01-29 |
20090029950 | Composition for Reducing the Exudation of Serum Proteins - Disclosed is a composition for reducing the exudation of the serum proteins. More specifically the composition of the present invention relates to a composition capable of improving conditions such as atopic dermatitis, atopic eczema, skin pruritus, atopic nasitis, atopic erythema or erythroderma, contact dermatitis, asthma, chronic obstructive pulmonary disease, etc. by reducing the exudation of the serum proteins in skin and mucosa. | 2009-01-29 |
20090029951 | CALCIUM/SODIUM SALT OF INOSITOL TRIPYROPHOSPHATE AS AN ALLOSTERIC EFFECTOR OF HEMOGLOBIN - The present invention relates to mixed calcium/sodium salt of inositol tripyrophosphate, methods of preparing and methods of use. The mixed calcium/sodium salt may be a monocalcium tetrasodium salt of inositol tripyrophosphate. Methods of use include administering the above salts in an effective amount to treat diseases caused by hypoxia or other conditions associated with inadequate function of the lungs or circulatory system, such as various types of cancer and Alzheimer's disease. | 2009-01-29 |
20090029952 | UNIQUE COMBINATION OF ACETYLSALICYLIC ACID, ETHYLENEDIAMINE DIHYDROIODIDE (EDDI), AND BUFFER FOR USE IN ANIMAL DRINKING WATER - A unique combinations include acetylsalicylic acid (aspirin), ethylenediamine dihydriodide (EDDI), potassium iodide, sodium acetate, and sodium diacetate, useful in helping poultry, swine, and cattle overcome certain symptoms after vaccination. The inventive combinations readily dissolve in water at room temperature to form an effective concentration for inclusion in the animal's drinking water. | 2009-01-29 |
20090029953 | 18-METHYL-19-NOR-17-PREGN-4-ENE-21,17-CARBOLACTONES, AS WELL AS PHARMACEUTICAL PREPARATIONS THAT CONTAIN THE LATTER - The invention relates to novel 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactones of general formula (I), where Z=O, H | 2009-01-29 |
20090029954 | PROGESTERONE-RECEPTOR ANTAGONIST FOR USE IN BRCA ALONE OR AS COMBINATION WITH ANTIESTROGEN - The present invention relates to the single use of the progesterone-receptor antagonist 11β-(4-acetylphenyl)-17β-hydroxy-17α-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue thereof for the prophylaxis and treatment of BRCA1- or BRCA2-mediated breast cancer, as well as to a combination comprising the progesterone-receptor antagonist 11β-(4-acetylphenyl)-17β-hydroxy-17α-(1,1,2,2,2-pentafluoroethyl)-estra-4,9-dien-3-one or a pharmaceutically acceptable derivative or analogue thereof, together with at least one pure antiestrogen, for the prophylaxis and treatment of BRCA1- or BRCA2-mediated breast cancer, ovarian cancer endometrial cancer, gastric cancer, colorectal cancer, endometriosis, myeloma, myoma and meningioma. | 2009-01-29 |
20090029955 | Pyridothienopyrimidine Derivatives - A pyridothienopyrimidine derivative of formula (I), | 2009-01-29 |
20090029956 | Substance mixture - A substance mixture comprising at least one glucocorticoid and at least one N-chloro compound and/or at least one O-chloro compound as well as a medicament containing such a substance mixture as well as the use and manufacture of such a medicament for the topical treatment of inflammations. | 2009-01-29 |
20090029957 | 8-BETA-SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGENS - The invention refers to 8β-substituted estra-1,3,5(10)-triene derivatives of general formula I | 2009-01-29 |
20090029958 | PHENETHANOLAMINE DERIVATIVES AS BETA2 ADRENORECEPTOR AGONISTS - The present invention relates to compounds according to formula (I), a process for preparing them, the intermediate compounds of the process and the use of the compounds in the manufacture of a medicament for use in treating diseases such as ARDS, pulmonary emphysema, bronchitis, bronchiectasis, COPD, asthma and rhinitis. The compounds are beta2 adrenoreceptor agonists. | 2009-01-29 |
20090029959 | Antiglucocorticoid Therapy for the Prevention of Neurological Damage in Premature Infants - This invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for preventing neurological damage associated with glucocorticoid therapy in ventilator-dependent low birth weight preterm infants. Mifepristone, a potent glucocorticoid receptor antagonist, can be used in these methods. | 2009-01-29 |
20090029960 | MACROCYCLIC COMPOUNDS USEFUL AS BASE INHIBITORS - The invention relates to novel macrocyclic compounds of the formula | 2009-01-29 |
20090029961 | Bio-Film Resistant Surfaces - The present invention relates to methods and compositions for rendering a surface resistant to bio-film formation by a combination of an alkanediol and an antimicrobial agent (and, optionally, an organic hydroxy acid). The invention provides for compositions which may be used to render surfaces bio-film resistant, articles having bio-film resistant surfaces, and methods for their preparation. The present invention may be advantageously applied to medical articles as well as articles used in non-medical contexts, such as child care or food preparation. | 2009-01-29 |
20090029962 | 2-AZETIDINEMETHANEAMINES AND 2-PYRROLIDINEMETHANEAMINES AS TAAR-LIGANDS - The present invention relates to compounds of formula I | 2009-01-29 |
20090029963 | PYRAZOL DERIVATIVES - The invention is concerned with novel pyrazol derivatives of formula (I), | 2009-01-29 |
20090029964 | Novel carbapenem compound - An orally administrable antibacterial agent which contains as an active ingredient a carbapenem compound represented by the formula [1] below, | 2009-01-29 |
20090029965 | Vasopressin V1a Antagonists - The present invention concerns compounds inter alia according to general formula 1 | 2009-01-29 |
20090029966 | COMBINATION THERAPY WITH PARP INHIBITORS - The present invention describes benzimidazole derivatives of Formula (I) which constitute potent PARP inhibitors in combination with temozolomide (TMZ). | 2009-01-29 |
20090029967 | ADENOSINE A2A RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXTRA-PYRAMIDAL SYNDROME AND OTHER MOVEMENT DISORDERS - There is disclosed a method for the treatment or prevention of Extra Pyramidal syndrome (EPS), dystonia, restless leg syndrome (RLS) or periodic leg movement in sleep (PLMS) comprising the administration of an adenosine A2a receptor antagonist, alone or in combination with other agents useful for treating EPS, dystonia, RLS or PLMS. | 2009-01-29 |
20090029968 | QUINAZOLINE DERIVATIVES USED AS INHIBITORS OF ERBB TYROSINE KINASE - A quinazoline derivative of the Formula I: | 2009-01-29 |
20090029969 | Thiophene Compounds -
This invention relates to thiophene compounds of formula (I) shown below:
| 2009-01-29 |
20090029970 | PAIN REMEDY CONTAINING ROCK INHIBITOR - Since a ROCK inhibitor exerts a potent analgesic effect by a single dose after the onset of a cartilage-related disease such as osteoarthritis, and can regenerate or suppress destruction of cartilage tissue and alleviate pain associated with cartilage diseases by multiple doses, administration of an therapeutically effective amount of the ROCK inhibitor to a patient with cartilage-related disease such as osteoarthritis or rheumatoid arthritis can treat the patient with cartilage-related disease and the ROCK inhibitor is thus useful. | 2009-01-29 |
20090029971 | SULFONYL-SUBSTITUTED BICYCLIC COMPOUNDS AS MODULATORS OF PPAR - Compounds as modulators of peroxisome proliferator activated receptors, pharmaceutical compositions comprising the same, and methods of treating disease using the same are disclosed. | 2009-01-29 |
20090029972 | Dibenzodiazepinone Analogues, Processes for Their Production and Their Use as Pharmaceuticals - The invention relates to biologically active dibenzodiazepinone analogs represented by Formula I, to methods of producing them, and their use in the preparation of medicaments for the treatment of neoplastic conditions | 2009-01-29 |
20090029973 | FUSED HETEROCYCLIC COMPOUND - The present invention relates to a compound represented by the formula: | 2009-01-29 |
20090029974 | Tumor Treatment with Gliotoxin Derivatives - The present invention describes the use of Notch2 inhibitors for producing a medicament for the treatment of tumours, which tumours are characterised by ligand-independent Notch2 fragments. | 2009-01-29 |
20090029975 | 1,3-BENZOTHIAZINONE DERIVATIVE AND USE THEREOF - A compound represented by the formula (I) or a salt thereof: (I) wherein R | 2009-01-29 |
20090029976 | BENZOFURAN AND BENZOTHIOPHENE-2-CARBOXYLIC ACID AMIDE DERIVATIVES - The present invention relates to compounds of formula I | 2009-01-29 |
20090029977 | DUAL MODULATORS OF 5HT2A AND D3 RECEPTORS - The present invention relates to compounds of the formula (I) | 2009-01-29 |
20090029978 | THIENO-(1,3)-OXAZIN-4-ONES WITH LIPASE INHIBITING ACTIVITY - The use of a compound comprising formula (I), or a salt, ester, amide or prodrug thereof in the treatment of obesity and related disorders. The invention also relates to novel compounds within formula (I), to processes for preparing them and pharmaceutical compositions containing them. In formula (I): A is an optionally substituted thienyl moiety, Y is O, S, or NR | 2009-01-29 |
20090029979 | 5-HTX MODULATORS - This invention relates to compounds which bind to serotonin receptors inside or outside the central nervous system, in particular compounds which bind to the 5-HT | 2009-01-29 |
20090029980 | C-7 Isoxazolinyl Quinolone / Naphthyridine Derivatives Useful as Antibacterial Agents - The present invention relates to C-7 isoxazolyl quinoline/naphthyridine derivatives useful as antimicrobial compounds, pharmaceutical compositions comprising said derivatives and the use of said derivatives and pharmaceutical compositions as antimicrobial agents against pathogenic microorganisms, particularly against resistant microbes. | 2009-01-29 |
20090029981 | SUBSTITUTED 4-PHENYLPIPERIDINES - The application relates to substituted 4-phenylpiperidines of the general formula and their salts, preferably their pharmaceutically acceptable salts, in which R | 2009-01-29 |
20090029982 | PROTEIN KINASE INHIBITORS - Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the structure (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, X, Z, L2 and w are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof. | 2009-01-29 |
20090029983 | NOVEL HETEROCYCLIC COMPOUNDS HAVING ANTI-HBV ACTIVITY - This application relates to novel fused tricyclic thienopyridines of Formulas I and II, which useful for treating Hepatitis B infection and other diseases. | 2009-01-29 |
20090029985 | PYRIDAZINE COMPOUNDS AND METHODS - The invention relates to novel chemical compounds, compositions and methods of making and using the same. In particular, the invention provides pyridazine compounds and/or related heterocyclic derivatives, compositions comprising the same, and methods of using pyridazine compounds and/or related heterocyclic derivatives and compositions comprising the same, for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications. | 2009-01-29 |
20090029986 | N-AROYL CYCLIC AMINES - Disclosed are N-aroyl cyclic amine derivatives having the formula: | 2009-01-29 |
20090029987 | Pharmaceutical Compositions for the Prevention and Treatment of Complex Diseases and Their Delivery by Insertable Medical Devices - The present invention relates to polyphenol-like compounds that are useful for inhibiting VCAM-1 expression, MCP-1 expression and/or SMC proliferation in a mammal. The disclosed compounds are useful for regulating markers of inflammatory conditions, including vascular inflammation, and for treatment and prevention of inflammatory and cardiovascular diseases and related disease states. | 2009-01-29 |
20090029988 | Hydroxyalkyl Substituted Imidazoquinolines - Certain imidazoquinolines with a hydroxymethyl or hydroxyethyl substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for preferentially inducing IFN-α biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed. | 2009-01-29 |
20090029989 | SUBSTITUTED PYRAZOLOPYRIMIDINES - Pyrazolo-pyrimidine derivatives are described herein. The described invention also includes methods of making such derivatives as well as methods of using the same in the treatment of diseases. | 2009-01-29 |
20090029990 | Dihydropteridinones in the treatment of respiratory diseases - The present invention relates to the use of dihydropteridinones of formula 1 | 2009-01-29 |
20090029991 | BENZAMIDE DERIVATIVES USEFUL AS HISTONE DEACETYLASE INHIBITORS - The invention concerns a compound of the formula (I) | 2009-01-29 |
20090029992 | SUBSTITUTED PYRAZOLE COMPOUNDS - Disclosed are protein kinase inhibitors, compositions comprising such inhibitors, and methods of use thereof. More particularly, disclosed are inhibitors of Aurora A (Aurora-2) protein kinase. Also disclosed are methods of treating diseases associated with protein kinases, especially diseases associated with Aurora-2, such as cancer. | 2009-01-29 |
20090029993 | METHODS OF AFFECTING GASTROINTESTINAL TRANSIT AND GASTRIC EMPTYING, AND COMPOUNDS USEFUL THEREIN - Methods and compounds are disclosed for affecting gastrointestinal motility and gastric emptying, which comprise inhibiting tryptophan hydroxylase (TPH) in patients in need thereof. | 2009-01-29 |
20090029994 | Trisubstituted amine compound - The present invention relates to a compound of the general formula (1): | 2009-01-29 |
20090029995 | HETERO BIARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS - This invention provides compounds defined by Formula I | 2009-01-29 |
20090029996 | Pyridazin-3(2H)-One Derivatives And Their Use As Pde4 Inhibitors - The invention relates to new therapeutically useful pyridazin-3(2H)-one derivatives, to processes for their preparation and to pharmaceutical compositions containing them. These compounds are potent and selective inhibitors of phosphodiesterase 4 (PDE4) and are thus useful in the treatment, prevention and suppression of related pathological conditions, diseases and disorders, in particular asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, topic dermatitis, psoriasis or irritable bowel disease. | 2009-01-29 |
20090029997 | Thiazole Derivatives and Use Thereof - The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries. | 2009-01-29 |
20090029998 | Thiazole Derivatives and Use Thereof - The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries. | 2009-01-29 |
20090029999 | Synephrine derivatives useful as anti-inflammatory agents - This invention provides compounds having the structural formula: | 2009-01-29 |
20090030000 | ANTIVIRAL AGENTS - This invention relates to compounds of formula I | 2009-01-29 |
20090030001 | THERAPEUTIC AGENT FOR CORNEAL DISEASE - A therapeutic agent for a corneal disease comprising irsogladine or a salt thereof as an active ingredient. The purpose is to find a substance capable of effectively treating/ameliorating a corneal disease which has been increased in the number of cases thereof in recent years and to provide a therapeutic agent for a corneal disease comprising the substance as an active ingredient. | 2009-01-29 |
20090030002 | Heterocyclic compounds and their uses - Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelodysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer. | 2009-01-29 |
20090030003 | AMINO-HETEROCYCLIC COMPOUNDS - The invention provides PDE9-inhibiting compounds of Formula (I), | 2009-01-29 |
20090030004 | SPECIFIC SALT, ANHYDROUS AND CRYSTALLINE FORM OF A DIHYDROPTERIDIONE DERIVATIVE - The present invention relates to a specific salt of a dihydropteridione derivative, namely the trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide, to its crystallisation in the form of an hydrate with water, to a process for the manufacture thereof, and to the use thereof in a pharmaceutical composition. | 2009-01-29 |
20090030005 | Combinations for the treatment of cancer - This invention is in the field of pharmaceutical agents and specifically relates to combinations, compositions, uses and methods for treating cancer. | 2009-01-29 |
20090030006 | SPIROKETAL DERIVATIVES AND USE THEREOF AS DIABETIC MEDICINE - The present invention provides a compound of Formula (I): | 2009-01-29 |
20090030007 | NOVEL SOLVATE AND CRYSTALLINE FORMS OF CARBAMOYL-CYCLOHEXANE DERIVATIVES - The present invention relates to novel solvate and crystalline forms of carbamoyl-cyclohexane derivatives and, more particularly, to novel solvate and crystalline forms of trans-1{4-[2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl]-cyclohexyl}-3,3-dimethyl-urea hydrochloride. Processes for the preparation of these forms, compositions containing these forms, and methods of use thereof are also described. | 2009-01-29 |
20090030008 | PIPERAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS - Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): | 2009-01-29 |
20090030009 | Heterobicyclic Carboxamides as Inhibitors for Kinases - The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula (I) and to the use of a compound of formula (I) for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in particular tumour diseases. | 2009-01-29 |
20090030010 | 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents - This invention relates to compounds of general formula I | 2009-01-29 |
20090030011 | TRIAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES - The invention relates to triazolopyridine derivatives of general formula (I), which are defined as cited in the description, to their pharmaceutically applicable salts and to their use as medicaments. | 2009-01-29 |
20090030012 | Pyridine, Pyrimidine and Pyrazine Derivatives as Cxcr3 Receptor Modulators - The invention encompasses compounds of Formula I or pharmaceutically acceptable salts thereof, which are modulators of the CXCR3 chemokine receptor function useful for the treatment or prevention of pathogenic inflammatory processes, autoimmune diseases or graft rejection processes. Methods of use and pharmaceutical compositions are also encompassed. | 2009-01-29 |
20090030013 | SUBSTITUTED TETRAHYDRO-QUINOLINE-SULFONAMIDE COMPOUNDS, THEIR PREPARATION AND USE AS MEDICAMENTS - The present invention refers to substituted tetrahydro-quinoline-sulfonamide compounds of general formula (I): | 2009-01-29 |
20090030014 | Indole Derivative Having Pgd2 Receptor Antagonist Activity - The present invention creates an indole derivative having DP receptor antagonistic activity and a pharmaceutical composition comprising the said compound as an active ingredient, and further a therapeutic agent for treating allergic diseases. | 2009-01-29 |
20090030015 | NOVEL MULTI-CYCLIC COMPOUNDS - Pharmaceutical compositions comprising at least one compound of the formulas (Ia) or (Ib) or (IIa) or (IIb) and a pharmaceutically acceptable carrier | 2009-01-29 |
20090030016 | BENZIMIDAZOLE POLY(ADP RIBOSE)POLYMERASE INHIBITORS - Compounds which inhibit the activity of poly(ADP-ribose)polymerase (PARP), compositions containing the compounds and methods of treating diseases using them are disclosed. | 2009-01-29 |
20090030017 | THERAPEUTIC AGENT FOR DYSKINESIA - The present invention relates to a therapeutic agent for dyskinesia excluding tremor, comprising 1,2-dihydropyridine compound, a salt thereof, or a solvate thereof, which shows AMPA receptor antagonism and is highly useful as a pharmaceutical drug. | 2009-01-29 |
20090030018 | Benzimidazole derivatives and their use for modulating the gabaalpha receptor complex - This invention relates to novel benzimidazole derivatives, pharmaceutical compositions containing these compounds, and methods of treatment therewith. | 2009-01-29 |